SanBio Co Ltd - ESG Rating & Company Profile powered by AI
Browse to the bottom of the webpage for potential risks for SanBio Co Ltd based on sector, geography and size. The Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Quality Education', 'Sustainable Cities & Communities' and 'Partnerships for the Goals'. Detailed ESG assessment of SanBio Co Ltd are accessed by logging in.
SanBio Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 2.0, social score of 3.2 and governance score of 0.0.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | SanBio Co Ltd | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does SanBio Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes SanBio Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes SanBio Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes SanBio Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes SanBio Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes SanBio Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes SanBio Co Ltd offer flexible work?
Sign up for free to unlockDoes SanBio Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes SanBio Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes SanBio Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes SanBio Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes SanBio Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes SanBio Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes SanBio Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes SanBio Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes SanBio Co Ltd disclose water use targets?
Sign up for free to unlockDoes SanBio Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid SanBio Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes SanBio Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes SanBio Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas SanBio Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes SanBio Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes SanBio Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes SanBio Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes SanBio Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes SanBio Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes SanBio Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes SanBio Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs SanBio Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes SanBio Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes SanBio Co Ltd disclose its waste policy?
Sign up for free to unlockDoes SanBio Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes SanBio Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes SanBio Co Ltd disclose energy use targets?
Sign up for free to unlockDoes SanBio Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes SanBio Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for SanBio Co Ltd
These potential risks are based on the size, segment and geographies of the company.
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.